Overall Score

Financial Strength

Current ratio remains solid at 2.32x, indicating adequate near-term liquidity.

Net debt is modest relative to EBITDA, with netDebtToEBITDATTM at -0.84x.

Cash generation is positive, with free cash flow TTM of $507.8M and free cash flow yield of 14.3%.

Profitability

Gross margin is 23.5%, but operating margin remains deeply negative at -33.3%.

TTM net margin is -40.9%, reflecting continued bottom-line losses.

Return on invested capital is negative at -0.89x, showing the business is still not earning its cost of capital.

Valuation

EV/Sales is 2.93x, which is reasonable for a specialty biotech with positive cash generation.

Price to free cash flow is 7.0x, suggesting the market is not pricing in extreme cash-flow expectations.

Negative earnings and book value metrics limit the usefulness of traditional earnings-based valuation multiples.

Balance Sheet Risk

Debt-to-assets is 0.73x, but leverage appears manageable given the company’s liquidity position.

Cash ratio of 0.74x provides a meaningful cushion against short-term obligations.

Negative tangible book value and net current asset value remain structural balance-sheet weaknesses.